AVI BioPharma raises $30M to finance lead DMD candidate
This article was originally published in Scrip
Executive Summary
AVI BioPharma, a US developer of RNA-based therapeutics, raised $30 million gross in a fully underwritten public offering of 20 million units at $1.50 per share. The share offering was priced at a 19% discount to the 31 March closing share price.